ReviewPost-screenCurrent endovascular treatment of acute stroke and future aspects
Introduction
After myocardial infarction and cancer, stroke is the third most common cause of death in the western world, affecting an estimated 700,000 Americans each year, and is the most common cause of severe disability [1]. Some 30–50% of stroke survivors do not regain functional independence and 15–30% of these remain permanently disabled. Thus, stroke is a massive financial and personal burden on our society [2]. For someone who is having a stroke ‘Time is Brain’. Earlier treatment is associated with better outcome. To achieve this, acute stroke protocols are initiated to identify patients within the therapeutic time window for thrombolytic and mechanical recanalization therapies.
In 1996, as a result of the National Institute of Neurological Disorder and Stroke (NINDS) and rtPA Stroke Study Group trial, the US Food and Drug Administration (FDA) approved IV thrombolysis with recombinant tissue plasminogen activator (rtPA, alteplase) for the treatment of ischemic stroke within 3 h of onset [3]. Thus, IV rtPA thrombolysis was the first approved treatment that attacks the acute vessel occlusion directly. It is now accepted as a class 1A level of evidence intervention for acute ischemic stroke [4].
Analysis of major randomized placebo-controlled IV rtPA stroke trials, as ATLANTIS I and II (Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke), ECASS I and II (European Cooperative Acute Stroke Study), and NINDS I and II showed a benefit up to 3 h from the onset of stroke symptoms and suggested a potential benefit beyond 3 h for some patients 5, 6. The ECASS-III trial confirmed a treatment window up to 4.5 h for IV rtPA therapy [7].
Despite its promise and the use of different drugs, the recanalization rates of IV rtPA for proximal arterial occlusion range from only 10% to 30% and the NINDS trial data showed a 12% increase at 3 months in better outcomes between the placebo and rtPA groups [8].
Section snippets
Drugs used in acute stroke therapy
Drug therapy is a relatively recent approach to the treatment of stroke, and a large amount of research is focused on finding effective new drugs that can minimize stroke damage. The most relevant drugs evaluated for acute stroke therapy are summarized in Table 1.
Endovascular therapy of acute stroke
The relatively high haemorrhage rates, in combination with the low complete recanalization rates, demonstrate the imitations of treatment solely with pharmacological agents. Especially in carotid terminus or basilar artery occlusions with large clot burden, the procedure takes time and may not achieve meaningful recanalization. Platelet-rich clots, old clots and calcified clots or fat emboli cannot be addressed. These factors substantiate the assumption that faster and more complete reperfusion
Intraarterial mechanical therapies
The limitations to IA lysis are related to clot characteristics. The response to the pharmacological agent may vary according to the source and type of clot. White platelet rich clots are more resistant to lytics than fresh red blood cell rich clots. De novo cardiac clots and paradoxial venous clots respond better than calcified clots from atherosclerotic plaques.
The therapeutic approach concerning these limitations changed dramatically in 2004 with the US Food and Drug Administration approval
Alternative reperfusion strategies
The alternative reperfusion strategies use the collateral vasculature of the brain as well as retrograde and reversed flow.
Retrograde reperfusion and flow reversal are experimental treatment techniques that cause total reversal of the cerebral circulation and perfusion of the venous system with arterial blood into the capillary bed, which is then physiologically proximal to the occluded artery.
Limitations
Delayed symptomatic reocclusion after initial endovascular stroke therapy can lead to sudden clinical deterioration and has been linked to poor clinical outcomes [59]. The rate of reocclusion after endovascular treatments is 18% [60]. This may be underestimated as many patients present with large clinical deficits at time of presentation and explain the low rate of good clinical outcome despite of a high rate of revascularization.
Conclusions
The advantages of pharmacological thrombolysis over mechanical means are: The drugs are easier to administer and – ‘Time is Brain’: they can be started faster. Future newer generation lytics and platelet inhibitors may be even more faster, effective and specific. The disadvantages are that often no success can be achieved, and although the therapy can be initiated quickly, the effect occurs slowly and the risk of local and systemic hemorrhagic complications is evident.
The major disadvantages of
References (60)
Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents
J. Biol. Chem.
(1994)Symptomatic delayed reocclusion after initial successful revascularization in acute ischemic stroke
J. Stroke Cerebrovasc. Dis.
(2010)Recommendations on stroke prevention, diagnosis, and therapy: report of the WHO Task Force on Stroke and other Cerebrovascular Disorders
Stroke
(1989)Heart disease and stroke statistics: 2008 update – a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Circulation
(2008)Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke
N. Engl. J. Med.
(1995)Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke – a statement for healthcare professionals from a Special Writing Group of the Stroke Council. American Heart Association
Circulation
(1996)Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rtPA stroke trials
Lancet
(2004)Endovascular approaches to acute stroke. Part 1. Drugs, devices, and data
Am. J. Neuroradiol.
(2008)Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
N. Engl. J. Med.
(2008)Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator: the rtPA Acute Stroke Study Group
Am. J. Neuroradiol.
(1993)
Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke
Stroke
Streptokinase in acute ischemic stroke: an individual patient data meta-analysis – the Thrombolysis in Acute Stroke Pooling Project
Stroke
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan
Stroke
PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke –PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism
Stroke
Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study – a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
J. Amer. Med. Assoc.
The neurotoxicity of tissue plasminogen activator?
J. Cereb. Blood Flow Metab.
Bolus fibrinolytic therapy in acute myocardial infarction
J. Amer. Med. Assoc.
Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study
Neurosurgery
A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke
Stroke
Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model
Thromb. Haemost.
Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase
Pathophysiol. Haemost. Thromb.
Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial
J. Thromb. Thrombolysis
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset
Stroke
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase
Stroke
Ancrod for the treatment of acute ischemic brain infarction
Stroke
Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits
Stroke
Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator
Neurology
The combined approach to lysis utilizing eptifibatide and rtPA in acute ischemic stroke: the CLEAR stroke trial
Stroke
Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial – Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)
Stroke
Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial
Stroke
Cited by (23)
Advantages and limitations of anesthesia and sedation practices used during endovascular revascularization therapy among acute ischemic stroke patients
2013, Journal of Radiology NursingCitation Excerpt :Endovascular intervention for the AIS population carries a 5% to 7% risk of serious procedural complications. Risk of a symptomatic hemorrhagic transformation (6% to 15%) is the one feared the most (Killer et al., 2010). Among others are ischemic complications (up to 7% of all cases), brain edema, cardiopulmonary complications, allergic reaction to contrast and medications, contrast-induced nephropathy, and even death (de Carvalho et al., 2012).
Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention
2012, Drug Discovery TodayCitation Excerpt :Emergency carotid artery stent placement was performed in a small study group with good clinical outcomes [55]. For a comprehensive overview on endovascular stroke therapy and about new promising pharmacological and mechanical treatment options refer to the recent review by Killer et al. [56]. Decompressive surgery has been performed for decades.
Longistatin, a novel plasminogen activator from vector ticks, is resistant to plasminogen activator inhibitor-1
2011, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Treatment of thrombo-occlusive diseases is one of the most challenging areas in medicine. Plasminogen activators (PAs) have great clinical significance as thrombolytic agents in the managements of cerebral and cardiac attacks [5]. PAs such as tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA) and others activate plasminogen, a circulating plasma zymogen, into its active form plasmin, a powerful serine protease, which in turn dissolves thrombi and restores circulation in thrombosed vasculature; thus, rescue the affected tissues/organs from the devitalizing events of thrombosis [1,6–8].
Fibrinolytic bacteria of indonesian fermented soybean: Preliminary study on enzyme activity and protein profile
2020, Food Science and Technology (Brazil)